Feasibility study of fertility preservation before neoadjuvant or adjuvant chemotherapy for breast cancer: PRESAGE

Trial Profile

Feasibility study of fertility preservation before neoadjuvant or adjuvant chemotherapy for breast cancer: PRESAGE

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 11 Jan 2018

At a glance

  • Drugs Tamoxifen (Primary) ; Follicle stimulating hormones
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms PRESAGE
  • Most Recent Events

    • 11 Jan 2018 New trial record
    • 09 Dec 2017 Results (n=50) assessing feasibility study of fertility preservation by controlled ovarian stimulation (COS) combined with Tamoxifene and oocyte +/- embryo cryopreservation before neoadjuvant (NAC) or adjuvant (AC) chemotherapy for breast cancer, were presented at the 40th Annual San Antonio Breast Cancer Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top